CU20080043A7 - Formulación de cápsula de pirfenidona y excipientes farmacéuticamente aceptables - Google Patents

Formulación de cápsula de pirfenidona y excipientes farmacéuticamente aceptables

Info

Publication number
CU20080043A7
CU20080043A7 CU20080043A CU20080043A CU20080043A7 CU 20080043 A7 CU20080043 A7 CU 20080043A7 CU 20080043 A CU20080043 A CU 20080043A CU 20080043 A CU20080043 A CU 20080043A CU 20080043 A7 CU20080043 A7 CU 20080043A7
Authority
CU
Cuba
Prior art keywords
formulation
pharmaceutically acceptable
acceptable excipients
pirfenidone capsule
pirfenidone
Prior art date
Application number
CU20080043A
Other languages
English (en)
Inventor
Kenneth Sultzbaugh
Ronald Vladyka
Ramachandran Radhakrishnan
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37898745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20080043(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of CU20080043A7 publication Critical patent/CU20080043A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CU20080043A 2005-09-22 2006-09-22 Formulación de cápsula de pirfenidona y excipientes farmacéuticamente aceptables CU20080043A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72025705P 2005-09-22 2005-09-22
PCT/US2006/037057 WO2007038315A2 (en) 2005-09-22 2006-09-22 Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

Publications (1)

Publication Number Publication Date
CU20080043A7 true CU20080043A7 (es) 2011-04-26

Family

ID=37898745

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20080043A CU20080043A7 (es) 2005-09-22 2006-09-22 Formulación de cápsula de pirfenidona y excipientes farmacéuticamente aceptables

Country Status (28)

Country Link
US (5) US7988994B2 (es)
EP (2) EP2431025A1 (es)
JP (3) JP5837732B2 (es)
KR (3) KR101675651B1 (es)
CN (3) CN103393607A (es)
AP (2) AP2012006231A0 (es)
AU (2) AU2006295440B2 (es)
BR (1) BRPI0616324A2 (es)
CA (2) CA2762013C (es)
CU (1) CU20080043A7 (es)
CY (1) CY1115544T1 (es)
DK (1) DK1940364T4 (es)
EA (1) EA030093B1 (es)
EC (1) ECSP088394A (es)
ES (1) ES2496144T5 (es)
GE (1) GEP20115303B (es)
IL (2) IL189273A (es)
MA (1) MA29875B1 (es)
MX (1) MX2008003882A (es)
NO (1) NO345131B1 (es)
NZ (3) NZ591443A (es)
PL (1) PL1940364T5 (es)
PT (1) PT1940364E (es)
SI (1) SI1940364T2 (es)
TN (1) TNSN08136A1 (es)
UA (2) UA99433C2 (es)
WO (1) WO2007038315A2 (es)
ZA (1) ZA200802237B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CA2667654C (en) 2006-12-18 2016-12-13 Intermune, Inc. Method of providing pirfenidone therapy to a patient
US20080242293A1 (en) * 2007-04-02 2008-10-02 Cequint, Inc. System and method for providing caller id name display in wireless communications system
WO2008147169A2 (es) * 2007-05-29 2008-12-04 Cell Therapy Technology, S.A. De C.V. Microemolsion conteniendo pirfenidona
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
WO2009111785A2 (en) * 2008-03-07 2009-09-11 Solanan, Inc. Treatment of sepsis with 5-ethyl-1-phenyl-2(1h)-pyridone and novel methods for synthesis
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
EP2389227A4 (en) * 2009-01-26 2012-08-08 Intermune Inc METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF
JP5730280B2 (ja) 2009-03-16 2015-06-03 パング バイオファーマ リミテッド 非カノニカル生物学的活性を有するヒスチジル−ｔＲＮＡシンテターゼスプライスバリアントを含む組成物および方法
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
CN101912395B (zh) * 2010-08-12 2012-09-26 北京凯因科技股份有限公司 一种含吡非尼酮的药物组合物及其制备方法
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
BR112013022766A2 (pt) 2011-03-08 2016-12-06 Auspex Pharmaceuticals Inc método de administração de d-pirfenidona e kit
CN102670632A (zh) * 2011-03-12 2012-09-19 赵海静 吡非尼酮在抑制皮肤瘢痕形成的医药用途
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
CA2819967C (en) * 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2968292A4 (en) 2013-03-15 2016-11-23 Intermune Inc METHOD FOR IMPROVING MICROVASCULAR INTEGRITY
CN114717206A (zh) 2013-03-15 2022-07-08 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
MY194303A (en) * 2013-12-13 2022-11-27 Novartis Ag Pharmaceutical dosage forms
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
ES2908096T3 (es) * 2014-04-11 2022-04-27 Gemvax & Kael Co Ltd Péptido con actividad inhibidora de la fibrosis y composición que lo contiene
WO2016059815A1 (ja) * 2014-10-15 2016-04-21 安良太 吾妻 癌化学予防薬
CA2937365C (en) * 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
TWI745396B (zh) * 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物
KR102051559B1 (ko) * 2016-12-09 2019-12-05 재단법인 아산사회복지재단 섬유증의 진단 또는 치료를 위한 스테아르산의 용도
KR20180100869A (ko) * 2017-03-02 2018-09-12 영진약품 주식회사 피르페니돈의 입자크기 조절에 따른 타정성이 개선된 약제학적 조성물 및 이의 제조방법
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
EP3511001B1 (en) 2018-01-12 2021-09-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Pirfenidone-containing tablet and capsule formulation
US20210205253A1 (en) * 2018-05-31 2021-07-08 The Asan Foundation Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis
WO2020003107A1 (en) * 2018-06-29 2020-01-02 Zenvision Pharma Llp Low dose oral pharmaceutical composition of pirfenidone or salt thereof
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
KR20220137699A (ko) * 2020-02-06 2022-10-12 가부시키가이샤 리보믹 망막하 고반사 병소 또는 망막하 고반사 병소를 수반하는 망막 질환의 치료제
US20230129866A1 (en) * 2020-03-13 2023-04-27 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CN115361950A (zh) 2020-04-01 2022-11-18 勃林格殷格翰国际有限公司 生物标记物在治疗纤维化病症中的用途
KR20230038644A (ko) * 2020-04-14 2023-03-21 엑스칼리버 파마슈티컬즈, 인크. 코로나바이러스 치료를 위한 피르페니돈
JP7490813B2 (ja) * 2020-04-22 2024-05-27 ユンジン ファーム．カンパニー、リミテッド 安全性と安定性が改善されたピルフェニドンを含む腸溶性製剤およびその製造方法
KR102764240B1 (ko) 2021-01-25 2025-02-11 주식회사 나이벡 섬유화 예방 및 치료용 펩타이드
CN117224429B (zh) * 2023-11-15 2024-02-06 南京天纵易康生物科技股份有限公司 一种含羟乙基纤维素作为崩解剂的烟酰胺/肽类固液分离护肤组合物及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
CA1049411A (en) † 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) * 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
ATE224712T1 (de) † 1993-05-07 2002-10-15 Solomon B Margolin Zusammensetzungen und verfahren zur reparatur und vorbeugung fibrotischer verletzungen
US5591766A (en) * 1993-12-03 1997-01-07 Cheil Foods & Chemicals, Inc. Solid oral formulations of pyridone carboxylic acids
US6090822A (en) * 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US5962478A (en) * 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
CA2403594A1 (en) * 2000-03-27 2002-09-18 Kyowa Hakko Kogyo Co., Ltd. Granules having good taking property
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
JP4280074B2 (ja) * 2001-04-25 2009-06-17 大正製薬株式会社 マルチプルユニット型徐放性錠剤
US7007089B2 (en) * 2001-06-06 2006-02-28 Akarnai Technologies, Inc. Content delivery network map generation using passive measurement data
US7512702B1 (en) * 2002-03-19 2009-03-31 Cisco Technology, Inc. Method and apparatus providing highly scalable server load balancing
US7139840B1 (en) * 2002-06-14 2006-11-21 Cisco Technology, Inc. Methods and apparatus for providing multiple server address translation
WO2004019758A2 (en) 2002-08-27 2004-03-11 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
WO2004019863A2 (en) * 2002-08-28 2004-03-11 Intermune, Inc. Combination therapy for treatment of fibrotic disorders
US7159034B1 (en) * 2003-03-03 2007-01-02 Novell, Inc. System broadcasting ARP request from a server using a different IP address to balance incoming traffic load from clients via different network interface cards
JP2006521300A (ja) * 2003-03-31 2006-09-21 プリヴァ−ラケマ，エー．エス． 活性物質として白金錯体を含有する医薬組成物およびその製造方法
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2004103296A2 (en) 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
MXPA06000178A (es) * 2003-07-01 2006-04-11 Pharmacia & Upjohn Co Llc Solidos modulados en la fase de difusion.
WO2005040758A2 (en) 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7825133B2 (en) 2003-11-14 2010-11-02 Shanghai Genomics, Inc. Derivatives of pyridone and the use of them
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US7584435B2 (en) * 2004-03-03 2009-09-01 Omniture, Inc. Web usage overlays for third-party web plug-in content
EP2305696A3 (en) * 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients

Also Published As

Publication number Publication date
EA030093B1 (ru) 2018-06-29
ECSP088394A (es) 2008-05-30
WO2007038315A3 (en) 2007-07-12
NZ591443A (en) 2013-04-26
AU2011201520A1 (en) 2011-04-28
AU2006295440A1 (en) 2007-04-05
KR20080046673A (ko) 2008-05-27
HK1117762A1 (en) 2009-01-23
MX2008003882A (es) 2009-02-27
EA200800881A1 (ru) 2008-08-29
NO20080759L (no) 2008-06-18
CA2620380C (en) 2012-10-30
UA115861C2 (uk) 2018-01-10
ZA200802237B (en) 2010-04-28
EP1940364B1 (en) 2014-06-11
AP2008004390A0 (en) 2008-04-30
EP1940364B2 (en) 2022-07-20
US20130165484A1 (en) 2013-06-27
CA2762013C (en) 2014-07-08
KR101645069B1 (ko) 2016-08-02
US7767225B2 (en) 2010-08-03
US8753679B2 (en) 2014-06-17
CA2620380A1 (en) 2007-04-05
AP2655A (en) 2013-05-07
SI1940364T2 (sl) 2022-11-30
MA29875B1 (fr) 2008-10-03
JP5837732B2 (ja) 2015-12-24
SI1940364T1 (sl) 2014-09-30
US7988994B2 (en) 2011-08-02
UA99433C2 (ru) 2012-08-27
BRPI0616324A2 (pt) 2011-06-14
DK1940364T3 (da) 2014-06-30
CN101267810A (zh) 2008-09-17
US8383150B2 (en) 2013-02-26
US20120015984A1 (en) 2012-01-19
JP2012224641A (ja) 2012-11-15
EP1940364A2 (en) 2008-07-09
DK1940364T4 (da) 2022-10-24
US20100152250A1 (en) 2010-06-17
CN103393607A (zh) 2013-11-20
PL1940364T3 (pl) 2014-11-28
JP5715101B2 (ja) 2015-05-07
KR101675651B1 (ko) 2016-11-11
NZ600129A (en) 2013-12-20
GEP20115303B (en) 2011-10-10
IL239868A0 (en) 2015-08-31
ES2496144T5 (es) 2022-11-21
US20090191265A1 (en) 2009-07-30
CA2762013A1 (en) 2007-04-05
AU2011201520B2 (en) 2013-04-11
AU2006295440B2 (en) 2011-01-06
NO345131B1 (no) 2020-10-12
JP2009509962A (ja) 2009-03-12
US20140242159A1 (en) 2014-08-28
ES2496144T3 (es) 2014-09-18
KR20130100381A (ko) 2013-09-10
IL189273A (en) 2016-09-29
EP2431025A1 (en) 2012-03-21
KR20140029554A (ko) 2014-03-10
PT1940364E (pt) 2014-09-04
WO2007038315A2 (en) 2007-04-05
TNSN08136A1 (en) 2009-07-14
CN103735530A (zh) 2014-04-23
AP2012006231A0 (en) 2012-04-30
PL1940364T5 (pl) 2023-02-27
IL189273A0 (en) 2008-06-05
NZ565957A (en) 2012-04-27
CY1115544T1 (el) 2017-01-04
JP2014169341A (ja) 2014-09-18

Similar Documents

Publication Publication Date Title
NO345131B1 (no) Kapselformulering av pirfenidon og farmasøytisk akseptable eksipienter
LUC00127I2 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
IL184735A0 (en) Pharmaceutical formulations and methods of use
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
DK1986679T3 (da) Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
LU93189I2 (fr) Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
MA28489B1 (fr) Preparations pharmaceutiques
TWI367212B (en) Dosage forms of palonosetron hydrochloride having improved stability and bioavailability
HUS1500034I1 (hu) Indolidon-származékok fibrózisos betegségek kezelésére vagy megelõzésére
IL188732A (en) Use of ibuprofen and famotidine in the preparation of medicaments
FR2873585B1 (fr) Nouvelles formulations galeniques de principes actifs
CY2018006I2 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
GB0524958D0 (en) Transdermal administration of active agents
EP1721604A4 (en) STABLE CAPSULE PREPARATION
IL180031A0 (en) Stable pharmaceutical formulations of benzimidazole compounds
IL184697A0 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts
EP1968609A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS
PL1655026T3 (pl) Zawierające diacereinę i meloksikam stałe preparaty farmaceutyczne
DK1798234T3 (da) Farmaceutisk sammensætning omfattende temozolomidester
DK1729734T3 (da) Spröjtetörrede farmaceutiske præparater
GB0610207D0 (en) New forms of active pharmaceutical ingredient
TH0601002495A (th) สารผสมตามสูตรทางเภสัชกรรมและวิธีการของการบำบัดรักษาซึ่งใช้สิ่งดังกล่าว
PL380757A1 (pl) Nowe pochodne epirubicyny, ich nowe zastosowanie medyczne oraz farmaceutycznie akceptowalna postać leku
HK1123205A (en) Orally absorbed pharmaceutical formulation and method of administration
EP1959940A4 (en) LOCALIZED DELIVERY OF ARZNEIC COMBINATIONS